Skip to content
Screener

CRISPR Therapeutics CRSP Total Liabilities

Total Liabilities at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.55B+34.8%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$129.46M-29.5%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$117.08M-4.5%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$316.36M-8.0%
Sana Biotechnology logo
Sana BiotechnologySANA
$254.35M+7.6%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$12.39M+29.6%

Other financials

Income statement

See full
Revenue$1.5M+68.6%
Operating income-$130.2M+12.2%
Net income-$122.9M+9.6%
EPS (diluted)-$1.28+19.0%

Balance sheet

See full
Cash & equivalents$423.3M+80.0%
Total debt$787.6M+259%
Total equity$1.8B-0.8%
Total assets$2.7B+25.8%

Cash flow

See full
Operating cash flow-$108.9M-102%
CapEx$504.0K+145%
Free cash flow-$109.4M-102%

Valuation

See full
Market cap$4.99B-2.6%
Enterprise value$5.36B+4.1%
P/S1,217×+1,082×

Profitability

See full
Operating margin-15,754.2%-17,253pp
Net margin-13,856.5%-15,058pp
FCF margin-9,777.6%-10,759pp

Returns & leverage

See full
Return on equity-31.2%+43.7pp
Debt / equity0.4×+0.3×
Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:48 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-204188
Line itemAs of / March 31, 2026As of / December 31, 2025
Long-term debt585,470
Operating lease liabilities, net of current portion183,560188,168
Other non-current liabilities5,9486,142
Total liabilities911,264343,430
Commitments and contingencies, see Note 7
Shareholders’ equity:
Common shares, CHF 0.03 nominal value, 132,477,166 shares authorized at March 31, 2026 and at December 31, 2025, 96,500,822 and 96,009,657 shares issued at March 31, 2026 and December 31, 2025, respectively, 96,385,506 and 95,894,341 shares outstanding at March 31, 2026 and December 31, 2025, respectively3,1153,087
Treasury shares, at cost, 115,316 shares at March 31, 2026 and at December 31, 2025(60)(60)

Item 1. Financial Statements

FAQ

What is CRISPR Therapeutics's total liabilities?
CRISPR Therapeutics (CRSP) reported total liabilities of $911.26M in Q1 2026.
How has CRISPR Therapeutics's total liabilities changed year-over-year?
CRISPR Therapeutics's total liabilities increased by 170.5% year-over-year, from $336.94M to $911.26M.
What is the long-term trend for CRISPR Therapeutics's total liabilities?
Over 5 years (2020 to 2025), CRISPR Therapeutics's total liabilities has grown at a 16.0% compound annual growth rate (CAGR), from $163.73M to $343.43M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about CRISPR Therapeutics's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude